|
1
|
Kaanders JHAM, Bussink J, Aarntzen EHJG, Braam P, Rütten H, van der Maazen RWM, Verheij M, van den Bosch S. [18F]FDG-PET-Based Personalized Radiotherapy Dose Prescription. Semin Radiat Oncol 2023; 33:287-297. [PMID: 37331783 DOI: 10.1016/j.semradonc.2023.03.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/20/2023]
Abstract
PET imaging with 2'-deoxy-2'-[18F]fluoro-D-glucose ([18F]FDG) has become one of the pillars in the management of malignant diseases. It has proven value in diagnostic workup, treatment policy, follow-up, and as prognosticator for outcome. [18F]FDG is widely available and standards have been developed for PET acquisition protocols and quantitative analyses. More recently, [18F]FDG-PET is also starting to be appreciated as a decision aid for treatment personalization. This review focuses on the potential of [18F]FDG-PET for individualized radiotherapy dose prescription. This includes dose painting, gradient dose prescription, and [18F]FDG-PET guided response-adapted dose prescription. The current status, progress, and future expectations of these developments for various tumor types are discussed.
Collapse
Affiliation(s)
- Johannes H A M Kaanders
- Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands..
| | - Johan Bussink
- Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands
| | - Erik H J G Aarntzen
- Department of Medical Imaging, Radboud university medical center, Nijmegen, The Netherlands
| | - Pètra Braam
- Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands
| | - Heidi Rütten
- Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands
| | | | - Marcel Verheij
- Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands
| | - Sven van den Bosch
- Department of Radiation Oncology, Radboud university medical center, Nijmegen, The Netherlands
| |
Collapse
|
|
2
|
Slyusarenko M, Shalaev S, Valitova A, Zabegina L, Nikiforova N, Nazarova I, Rudakovskaya P, Vorobiev M, Lezov A, Filatova L, Yevlampieva N, Gorin D, Krzhivitsky P, Malek A. AuNP Aptasensor for Hodgkin Lymphoma Monitoring. BIOSENSORS 2022; 12:23. [PMID: 35049651 PMCID: PMC8774100 DOI: 10.3390/bios12010023] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Revised: 12/27/2021] [Accepted: 12/29/2021] [Indexed: 06/14/2023]
Abstract
A liquid biopsy based on circulating small extracellular vesicles (SEVs) has not yet been used in routine clinical practice due to the lack of reliable analytic technologies. Recent studies have demonstrated the great diagnostic potential of nanozyme-based systems for the detection of SEV markers. Here, we hypothesize that CD30-positive Hodgkin and Reed-Sternberg (HRS) cells secrete CD30 + SEVs; therefore, the relative amount of circulating CD30 + SEVs might reflect classical forms of Hodgkin lymphoma (cHL) activity and can be measured by using a nanozyme-based technique. A AuNP aptasensor analytics system was created using aurum nanoparticles (AuNPs) with peroxidase activity. Sensing was mediated by competing properties of DNA aptamers to attach onto surface of AuNPs inhibiting their enzymatic activity and to bind specific markers on SEVs surface. An enzymatic activity of AuNPs was evaluated through the color reaction. The study included characterization of the components of the analytic system and its functionality using transmission and scanning electron microscopy, nanoparticle tracking analysis (NTA), dynamic light scattering (DLS), and spectrophotometry. AuNP aptasensor analytics were optimized to quantify plasma CD30 + SEVs. The developed method allowed us to differentiate healthy donors and cHL patients. The results of the CD30 + SEV quantification in the plasma of cHL patients were compared with the results of disease activity assessment by positron emission tomography/computed tomography (PET-CT) scanning, revealing a strong positive correlation. Moreover, two cycles of chemotherapy resulted in a statistically significant decrease in CD30 + SEVs in the plasma of cHL patients. The proposed AuNP aptasensor system presents a promising new approach for monitoring cHL patients and can be modified for the diagnostic testing of other diseases.
Collapse
Affiliation(s)
- Maria Slyusarenko
- Subcellular Technology Laboratory, Department of Hematology and Chemotherapy and Department of Radionuclide Diagnostics, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia; (M.S.); (S.S.); (A.V.); (L.Z.); (N.N.); (I.N.); (L.F.); (P.K.)
- The Faculty of Physics and Center for Molecular and Cell Technologies, Saint-Petersburg State University, 199034 St. Petersburg, Russia; (M.V.); (A.L.); (N.Y.)
| | - Sergey Shalaev
- Subcellular Technology Laboratory, Department of Hematology and Chemotherapy and Department of Radionuclide Diagnostics, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia; (M.S.); (S.S.); (A.V.); (L.Z.); (N.N.); (I.N.); (L.F.); (P.K.)
| | - Alina Valitova
- Subcellular Technology Laboratory, Department of Hematology and Chemotherapy and Department of Radionuclide Diagnostics, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia; (M.S.); (S.S.); (A.V.); (L.Z.); (N.N.); (I.N.); (L.F.); (P.K.)
| | - Lidia Zabegina
- Subcellular Technology Laboratory, Department of Hematology and Chemotherapy and Department of Radionuclide Diagnostics, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia; (M.S.); (S.S.); (A.V.); (L.Z.); (N.N.); (I.N.); (L.F.); (P.K.)
| | - Nadezhda Nikiforova
- Subcellular Technology Laboratory, Department of Hematology and Chemotherapy and Department of Radionuclide Diagnostics, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia; (M.S.); (S.S.); (A.V.); (L.Z.); (N.N.); (I.N.); (L.F.); (P.K.)
| | - Inga Nazarova
- Subcellular Technology Laboratory, Department of Hematology and Chemotherapy and Department of Radionuclide Diagnostics, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia; (M.S.); (S.S.); (A.V.); (L.Z.); (N.N.); (I.N.); (L.F.); (P.K.)
| | - Polina Rudakovskaya
- Center for Photonics and Quantum Materials, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia; (P.R.); (D.G.)
| | - Maxim Vorobiev
- The Faculty of Physics and Center for Molecular and Cell Technologies, Saint-Petersburg State University, 199034 St. Petersburg, Russia; (M.V.); (A.L.); (N.Y.)
| | - Alexey Lezov
- The Faculty of Physics and Center for Molecular and Cell Technologies, Saint-Petersburg State University, 199034 St. Petersburg, Russia; (M.V.); (A.L.); (N.Y.)
| | - Larisa Filatova
- Subcellular Technology Laboratory, Department of Hematology and Chemotherapy and Department of Radionuclide Diagnostics, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia; (M.S.); (S.S.); (A.V.); (L.Z.); (N.N.); (I.N.); (L.F.); (P.K.)
| | - Natalia Yevlampieva
- The Faculty of Physics and Center for Molecular and Cell Technologies, Saint-Petersburg State University, 199034 St. Petersburg, Russia; (M.V.); (A.L.); (N.Y.)
| | - Dmitry Gorin
- Center for Photonics and Quantum Materials, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia; (P.R.); (D.G.)
| | - Pavel Krzhivitsky
- Subcellular Technology Laboratory, Department of Hematology and Chemotherapy and Department of Radionuclide Diagnostics, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia; (M.S.); (S.S.); (A.V.); (L.Z.); (N.N.); (I.N.); (L.F.); (P.K.)
| | - Anastasia Malek
- Subcellular Technology Laboratory, Department of Hematology and Chemotherapy and Department of Radionuclide Diagnostics, N.N. Petrov National Medical Research Center of Oncology, 197758 St. Petersburg, Russia; (M.S.); (S.S.); (A.V.); (L.Z.); (N.N.); (I.N.); (L.F.); (P.K.)
| |
Collapse
|
|
3
|
Illidge T, Mikhaeel NG, Specht L, Yahalom J. Lymphoma: advances in imaging and radiotherapy - introductory editorial. Br J Radiol 2021; 94:20219005. [PMID: 34677091 DOI: 10.1259/bjr.20219005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Affiliation(s)
- Tim Illidge
- Manchester NIHR Biomedical Research Centre, University of Manchester, Christie Hospital, Manchester, United Kingdom
| | - N George Mikhaeel
- Guy's & St Thomas' NHS Foundation Trust and King's College University, London, United Kingdom
| | - Lena Specht
- Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Joachim Yahalom
- Memorial Sloan Kettering Cancer Center, New York, United States
| |
Collapse
|